- Neuroendocrine Cancer
- Newly Diagnosed
- Carcinoid & Neuroendocrine Tumor Patient Community
- Doctor Database
- Clinical Trials
- Educational Resources
- Additional Resources
- Join Us For a Cure
- Researching Funding Opportunities
- Current Research Grants
- Previous Research Grants
- Research Approach
- Board of Scientific Advisors
- Research Results
- About Us
- CFCF News
- Founder Nancy Lindholm
- Corporate Sponsorship
Lauren and Nick.
Dave, Suzi, Lauren - Philadelphia, PA
Exciting Additions to CFCF Research
Today, I am delighted to announce that Andy Futreal Ph.D. has joined the Caring for Carcinoid Foundation’s Board of Scientific Advisors.
Dr. Futreal is co-founder and director of the Cancer Genome Project, and a senior investigator at the Wellcome Trust Sanger Institute. Dr. Futreal's work has focused on the genetics of human cancer. His accomplishments include identification of susceptibility genes for breast and ovarian cancers as well as identification of somatic mutations in melanoma, lung cancer, T-cell leukemias, and renal cancer. Currently, Dr. Futreal’s work is focused on expanding characterization of cancer to whole genome sequencing and applying this information to impact cancer treatment.
Dr. Futreal brings additional expertise to CFCF’s esteemed Board of Scientific Advisors. Furthermore, his joining us to advance cures for neuroendocrine cancers underscores the fact that the neuroendocrine tumor research community is growing. Since its inception, CFCF has worked to promote collaboration and to attract talented scientists from diverse fields whose work can impacts neuroendocrine tumor research and understanding.
Over the years, it has been exciting to watch more and more researchers enter the field as funded-scientists, advisors, and other interested parties. As neuroendocrine tumor incidence rates rise, so does the number of scientists and pharmaceutical companies working to increase scientific understanding of these cancers and develop treatment strategies for patients with carcinoid cancer, pancreatic neuroendocrine, and related neuroendocrine cancers.
Today, CFCF is also announcing two new research grants totaling $500,000 issued through a partnership with the American Association for Cancer Research. The mission of the American Association for Cancer Research (AACR) is to prevent and cure cancer. Founded in 1907, the AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research.
CFCF enthusiastically partnered with the AACR to attract investigators pursuing innovative ideas and approaches that have a direct application and relevance to carcinoid cancer or pancreatic neuroendocrine tumors. We were specifically seeking individuals with expertise in other areas of cancer research with promising ideas that were different from other ongoing neuroendocrine tumor research projects.
The result was incredible! AACR and CFCF issued two innovative awards – each pursuing a novel treatment strategy for patients with neuroendocrine tumors! Click here to read more about these exciting awards or visit Research Grants on our website.
As we begin this new partnership with the AACR, we were pleased to do so with our previous research partner, the Raymond and Beverly Sackler Fund for the Arts and Sciences. The Raymond and Beverly Sackler Fund for the Arts and Sciences previously partnered with CFCF to launch Dr. Matthew Meyerson’s large scale genome study of carcinoid. In the same offering as the CFCF-AACR Awards, the Raymond and Beverly Sackler Fund for the Arts and Sciences partnered with the AACR to issue to fellowships to allow young investigators to begin careers in neuroendocrine cancer research. Click here for more information.
In 2010, I addressed the FDA on behalf of patients with neuroendocrine tumors stating, “It is truly a hopeful time for patients. There is increased research and scientific interest at academic institutions. There is increased interest from the pharmaceutical industry manifesting in more clinical trials for patients. This is an ideal time for the FDA to revisit its approach to reviewing Orphan Drug Marketing Applications."
Today, as we add expertise to our Board of Scientific Advisors and announce research projects to explore two novel treatment strategies for neuroendocrine cancer patients, we continue to gain momentum. In 2005, Nancy Lindholm founded the Caring for Carcinoid Foundation to discover cures for neuroendocrine cancers. It is because of Nancy and all patients that we are where we are today - your refusing to accept the current status quo; your willingness to support one another; your seeking out experts to obtain diagnosis and care; your participation in events to raise funds and awareness for neuroendocrine cancer research; your support of research; your willingness to participate in research through clinical trials, tumor banking efforts, and patient registries; and the myriad of other ways. Thank you all for being a part of today’s exciting achievements! To learn more about the ways patients are driving cures for neuroendocrine cancers, please read Nancy’s blog by clicking here.